FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma.

ABSTRACT:

Background

Despite the scarcity of data based on randomized trials, FOLFIRINOX is widely used in the management of borderline resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAPC). We investigated the clinical outcomes of neoadjuvant FOLFIRINOX in patients with BRPC and LAPC.

Methods

This single-center retrospective analysis included a total of 199 consecutive patients with BRPC or LAPC who received conventional or modified FOLFIRINOX between February 2013 and January 2017. An independent radiologist reviewed all baseline computed tomography or magnetic resonance imaging scans were reviewed for vascular invasion status.

Results

With median follow-up duration of 40.3 months [95% confidence interval (CI), 36.7-43.8] in surviving

SUBMITTER: Yoo C 

PROVIDER: S-EPMC7498966 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature